Summary of Study ST002302

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001475. The data can be accessed directly via it's Project DOI: 10.21228/M82M60 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002302
Study TitleIntegrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab
Study SummaryBackground: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 receptors, has been widely used in AD because of its efficacy. However, metabolic changes occurring in patients with AD in response to dupilumab remains unknown. In this study, we integrated metabolomics and lipidomics analyses with clinical data to explore potential metabolic alterations associated with dupilumab therapeutic efficacy. In addition, we investigate whether the development of treatment side effects was linked to the dysregulation of metabolic pathways. Methods: A total of 33 patients with AD were included in the current study, with serum samples collected before and after treatment with dupilumab. Comprehensive metabolomic and lipidomic analyses have previously been developed to identify serum metabolites (including lipids) that vary among treatment groups. An orthogonal partial least squares discriminant analysis model was established to screen for differential metabolites and metabolites with variable importance in projection > 1 and p < 0.05 were considered potential metabolic biomarkers. MetaboAnalyst 5.0 was used to identify related metabolic pathways. Patients were further classified into two groups, well responders (n = 19) and poor responders (n = 14), to identify differential metabolites between the two groups. Results: The results revealed significant changes in serum metabolites before and after 16 weeks of dupilumab treatment. Variations in the metabolic profile were more significant in the well-responder group than in the poor-responder group. Pathway enrichment analysis revealed that differential metabolites derived from the well-responder group were mainly involved in glycerophospholipid metabolism, valine, leucine and isoleucine biosynthesis, the citrate cycle, arachidonic acid metabolism, pyrimidine metabolism, and sphingolipid metabolism. Conclusion: Serum metabolic profiles of patients with AD varied significantly after treatment with dupilumab. Differential metabolites and their related metabolic pathways may provide clues for understanding the effects of dupilumab on patient metabolism.
Institute
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Last NameZhang
First NameLishan
AddressNo.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
Email429647356@qq.com
Phone+86-18612636397
Submit Date2022-10-01
Raw Data AvailableYes
Raw Data File Type(s)mzXML
Analysis Type DetailGC-MS/LC-MS
Release Date2022-10-18
Release Version1
Lishan Zhang Lishan Zhang
https://dx.doi.org/10.21228/M82M60
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA226584B11After dupilumab treatment
SA226585B10After dupilumab treatment
SA226586B9After dupilumab treatment
SA226587B12After dupilumab treatment
SA226588B13After dupilumab treatment
SA226589B15After dupilumab treatment
SA226590B14After dupilumab treatment
SA226591B8After dupilumab treatment
SA226592B7After dupilumab treatment
SA226593B2After dupilumab treatment
SA226594B1After dupilumab treatment
SA226595B3After dupilumab treatment
SA226596B4After dupilumab treatment
SA226597B6After dupilumab treatment
SA226598B5After dupilumab treatment
SA226599B16After dupilumab treatment
SA226600B17After dupilumab treatment
SA226601B29After dupilumab treatment
SA226602B28After dupilumab treatment
SA226603B27After dupilumab treatment
SA226604B30After dupilumab treatment
SA226605B31After dupilumab treatment
SA226606B33After dupilumab treatment
SA226607B32After dupilumab treatment
SA226608B25After dupilumab treatment
SA226609B26After dupilumab treatment
SA226610B19After dupilumab treatment
SA226611B18After dupilumab treatment
SA226612B20After dupilumab treatment
SA226613B21After dupilumab treatment
SA226614B24After dupilumab treatment
SA226615B23After dupilumab treatment
SA226616B22After dupilumab treatment
SA226617A32Before dupilumab treatment
SA226618A33Before dupilumab treatment
SA226619A31Before dupilumab treatment
SA226620A30Before dupilumab treatment
SA226621A9Before dupilumab treatment
SA226622A8Before dupilumab treatment
SA226623A10Before dupilumab treatment
SA226624A11Before dupilumab treatment
SA226625A14Before dupilumab treatment
SA226626A12Before dupilumab treatment
SA226627A7Before dupilumab treatment
SA226628A6Before dupilumab treatment
SA226629A2Before dupilumab treatment
SA226630A1Before dupilumab treatment
SA226631A3Before dupilumab treatment
SA226632A4Before dupilumab treatment
SA226633A5Before dupilumab treatment
SA226634A15Before dupilumab treatment
SA226635A13Before dupilumab treatment
SA226636A16Before dupilumab treatment
SA226637A24Before dupilumab treatment
SA226638A26Before dupilumab treatment
SA226639A27Before dupilumab treatment
SA226640A29Before dupilumab treatment
SA226641A28Before dupilumab treatment
SA226642A23Before dupilumab treatment
SA226643A25Before dupilumab treatment
SA226644A18Before dupilumab treatment
SA226645A22Before dupilumab treatment
SA226646A19Before dupilumab treatment
SA226647A17Before dupilumab treatment
SA226648A20Before dupilumab treatment
SA226649A21Before dupilumab treatment
SA226650QC02Control
SA226651QC03Control
SA226652QC04Control
SA226653QC06Control
SA226654QC01Control
SA226655QC07Control
SA226656QC05Control
Showing results 1 to 73 of 73
  logo